CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK’s Medicines and Healthcare Products Regulatory ...

Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of the transthyretin (TTR) protein that can damage vital ...

To identify DNA methylation sites associated with hATTR and compare patients affected with the disorder with asymptomatic carriers and noncarriers, they tested more than 700,000 sites in 80 ...

The mechanism of siRNAs consists of silencing a portion of RNA involved in causing the disease. The Food and Drug Administration (FDA) has approved Onpattro (patisiran; Alnylam) infusion for the ...

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ ALNY lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary ...

The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...

WASHINGTON – Angel says her family has been living with a rare disease they called “the curse” for generations. Known as hATTR Amyloidosis, the life-threatening condition was first accurately ...

The FDA has granted Fast Track designation to vutrisiran (Alnylam) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The Food and Drug ...